This is a past event. Registration is closed. View other OBN events.
Programme
- Delegate Registration
- Morning: Exhibition/Workshops/Partnering
- Delegate Lunch
- Afternoon: Exhibition/Workshops/Partnering
- BioForward Networking Drinks
- Workshop 1 • A Guide to the Latest Updates in R&D Tax Credits
Katy RabindranResearch & Development (R&D) tax relief can provide valuable financial support if you are a business that is investing in innovation and developing new processes, products or services. Understanding exactly how the R&D tax relief regimes work after changes come into force in April 2023 and April 2024 may be of critical importance to your financial projections. Join BDO’s Tax Director, Katy Rabindran for an update on these latest changes.
Katy Rabindran
Tax Director of BDO LLP
- Workshop 2 • Accessing the NHS • A Guide for Medical Device Companies
Neil RobertsThis session, led by Neil Roberts, CEO of South East Health Technologies Alliance (SEHTA) will provide advice and tips for medical device companies seeking entry into NHS. The session will cover regulatory requirements and approval processes necessary for medical devices to be accepted and utilized within the NHS infrastructure, and also the importance of aligning your product development with NHS priorities and challenges. Additionally, the session will provide valuable insights into building successful collaborations with key stakeholders within the NHS.
Neil Roberts
CEO of SEHTA
- Workshop 3 • Value inflection points in product development & company valuation
Paul Holmes•Prateet MinhasThis session will cover key milestones, “Value inflection points” in product development at which company valuation changes. The session will also include an overview of market research required to prepare for each milestone to maximize value for the shareholders of the company.
Paul Holmes
Managing Director, Commercial Advisory of Syneos Health
Prateet Minhas
Managing Director, Value & Access of Syneos Health
- Workshop 4 • Accelerating patient access to cell and gene therapies via integrated CRO, CDMO and Sponsor partnership
Jennifer PietrowskiCell therapies represent an exciting new treatment paradigm, a potentially viable treatment option for many eligible patients, with multiple global approvals expected in the coming years. As with any new and emerging advanced therapy, delivering on that promise requires navigating product and patient journeys that are unique from those that have long-dominated pharmaceutical development. From manufacturing and complex logistics to regulatory pathways and patient recruitment, multiple sectors, key stakeholders, and processes must be carefully and consistently aligned to patient-critical pathways. Patient challenges and operating model complexities still require further optimization to improve accessibility. Difficulties achieving commercial scale, labor-intensive processes due to lack of standardization/automation, and complex supply chain needs are all examples of current challenges that have yet to be fully addressed and further optimized.
In this session, attendees will gain insights into the complexities of the cell and gene therapy (CGT) ecosystem and will learn about the role of a CRO/CDMO partner in optimizing the journey and accelerating the path from study concept through to manufacture, for the benefit of patients.
Key takeaways will include:
• An understanding of the scale of complexity of products and patient journeys for cell and gene therapies
• Best practices for aligning clinical and commercial processes and workflows to patient-critical multidisciplinary pathways, instilling efficiency, accelerating timelines and helping reduce costs
• Real world case study demonstrating improvement of patient experience
Jennifer Pietrowski
Senior Director, Project Management Haematology/Oncology of PPD, part of Thermo Fisher Scientific
- Workshop 5 • Top tips and insights to fundraising, listing and other liquidity events
Shawn ManningThis workshop will offer valuable guidance for companies looking to raise funds achieve a liquidity event, including a successful public listing in the UK, and will cover essential tips and insights to facilitate these goals. Led by Shawn Manning, MD of Akesios Associates, the session will include information on regulatory requirements, disclosure obligations, and the steps involved in the listing procedure. Additionally, Shawn will provide valuable insights into the UK's financial market landscape helping you make informed decisions when considering your company’s aspirations to create liquidity for shareholders.
Shawn Manning
Managing Director of Akesios Associates
- Workshop 6 • Making your IP work for you
Kirsty DolphinThis workshop will delve into the strategic management of intellectual property (IP) to maximize its value and benefits. Kirsty Dolphin, Partner at Venner Shipley, will lead the session and share her key insights and tips on how businesses can effectively leverage their IP assets. The session will cover various aspects including the importance of protecting IP through patents, trademarks, and copyrights, as well as how to commercialize and license your IP.
Kirsty Dolphin
Partner at Venner Shipley
- Workshop 7 • A Guide to Financial Management for Early-stage Companies
Lars OttevangerThis workshop will provide top tips tailored to help early-stage life-sciences businesses effectively manage their finances. The host will outline key financial principles and industry specific practices essential for the success of emerging companies. Topics covered include efficiently managing your budget and cashflow, creating a solid financial plan, insights in budgeting for different phases, fundraising and strategic financial decision making.
Lars Ottevanger
Capital Advisory Associate at F.INSTITUTE
- Scheduled Partnering Meetings
- Exhibition Hall Open